Search clinical trials for: OMS102

Total 39 results

IntraPace, Inc

Completed

Safety Evaluation of the LGL102 in Obese Subjects Treated With OMS102

Obesity | Morbid Obesity

Germany
EMS

Not yet recruiting

Efficacy and Safety of OMA102 in the Treatment of Female Pattern Hair Loss (GENERA)

Female Pattern Baldness

Brazil
Omeros Corporation

Completed

Exploratory Study of OMS302 Injection in Subjects Undergoing Unilateral Cataract Extraction by Phacoemulsification.

Cataract Extraction

United States
Omeros Corporation

Recruiting

Safety and Efficacy Study of OMS906 in Patients With C3G and ICGN

C3 Glomerulopathy | Idiopathic Immune Complex-Mediated Glomerulonephritis

Lithuania, New Zealand, Poland, Tunisia, Turkey, United Kingdom
Omeros Corporation

Completed

Safety and Efficacy of OMS302 in Subjects Undergoing Unilateral Cataract Extraction With Lens Replacement (CELR)

Cataract

United States
Tianjin Medical University Cancer Institute and...

Recruiting

Fruquintinib Combined With TAS102 for Advanced Gastric Cancer

Gastric Cancer

China
Omeros Corporation

Recruiting

Study of the Safety and Efficacy of OMS906 in Patients With Paroxysmal Nocturnal Hemoglobinuria

Paroxysmal Nocturnal Hemoglobinuria

Ukraine
Omeros Corporation

Recruiting

Long-Term Safety, Tolerability and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria

Paroxysmal Nocturnal Hemoglobinuria

Switzerland, Germany, Ukraine, United Kingdom
Omeros Corporation

Terminated

Intraoperative Floppy Iris Syndrome Undergoing Intraocular Lens Replacement Surgery

Intraocular Lens Replacement | Intraoperative Floppy Iris Syndrome

Austria, Germany
Elpiscience Biopharma, Ltd.

Completed

A Study of ES102 (OX40 Agonist) in Patients With Advanced Solid Tumors

Neoplasms | Solid Tumors | Malignant Tumor

China
GamaMabs Pharma

Completed

First In Human Safety, Pharmacokinetics and Anti-tumoral Activity of GM102 in Gynecological Cancers

Neoplasm, Gynecologic

France, Belgium, United Kingdom
Afimmune

Completed

Safety And Efficacy Study Of Orally Administered DS102 In Patients With Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

United Kingdom
DS Biopharma

Completed

Safety and Efficacy Study of Orally Administered DS102 in Healthy Subjects

Healthy

Ireland
Ipsen

Terminated

Define the Optimal Uptake Time of 68Ga-OPS202 When Used as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Newly Diagnosed Breast Cancer

Breast Cancer

Austria
Afimmune

Recruiting

Pharmacokinetics, Pharmacodynamics and Safety of Epeleuton in Patients With Sickle Cell Disease

Sickle Cell Disease

United States
Afimmune

Terminated

Efficacy and Safety of Orally Administered DS102 in Patients With Acute Alcoholic Hepatitis

Severe Acute Decompensated Alcoholic Hepatitis

United States, Georgia
Ipsen

Completed

68Ga-OPS202 Study for Diagnostic Imaging of GEP NET

Gastroenteropancreatic Neuroendocrine Tumors

Switzerland
Omeros Corporation

Completed

Pharmacokinetic, Safety and Efficacy Study of OMS201 in Subjects Undergoing Retrograde Ureteroscopic Removal of Upper Urinary Tract Stones

Urinary Calculi | Renal Calculi | Kidney Stones | Urinary Stones | Urinary Tract Stones

United States
Ipsen

Completed

To Evaluate the Optimal Dose of 68Ga-OPS202 as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)

Gastro-Enteropancreatic Neuroendocrine Tumor

United States, Austria, Denmark
Omeros Corporation

Completed

Pharmacokinetic and Safety Study of OMS201 in Subjects Undergoing Ureteroscopic Treatment for Removal of Urinary Tract-Located Stones

Urinary Calculi | Urinary Stones | Urinary Tract Stones

United States
Afimmune

Terminated

Assess Efficacy and Safety of Epeleuton in Patients With Hypertriglyceridemia and Type 2 Diabetes (TRIAGE)

Type 2 Diabetes | Hypertriglyceridemia

Georgia, United States, Germany, Israel, Latvia, Switzerland
Elpiscience Biopharma, Ltd.
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

A Study of ES102 (OX40 Agonist) in Combination With JS001 in Patients With Advanced Solid Tumors

Neoplasms | Solid Tumor | Malignant Tumor

China
Omeros Corporation

Recruiting

Safety and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria Patients With a Sub-optimal Response to Ravulizumab

Paroxysmal Nocturnal Hemoglobinuria

Germany, Greece, Switzerland, United Kingdom
GamaMabs Pharma

Completed

Study for Evaluation of Murlentamab (GM102) Anti-tumoral Activity in Colorectal Cancers

Colorectal Cancer

Belgium, Czechia
SK Chemicals Co., Ltd.

Completed

Study to Assess the Efficacy and Safety of SK-MS10 in Subjects With Acute and Chronic Gastritis

Erosive Gastritis

Korea, Republic of
Omeros Corporation

Completed

Safety, Efficacy and Pharmacokinetics of OMS302 in Subjects Undergoing Intraocular Lens Replacement With Phacoemulsification (OMS302-ILR-004)

Intraocular Lens Replacement

United States, Netherlands
Omeros Corporation

Completed

Safety and Efficacy of OMS302 in Subjects Undergoing Intraocular Lens Replacement With Phacoemulsification (OMS302-ILR-003)

Intraocular Lens Replacement

United States
Wuhan Union Hospital, China

Recruiting

Safety of Cetuximab and Trifluridin Tipiracil as the Third-line Therapy in the RASwt mCRC

Colorectal Neoplasms Malignant

China
Borstkanker Onderzoek Groep
UMC Utrecht; Erasmus Medical Center; Servier; BOOG Study Center

Active, not recruiting

TAS102 in Patients With ER-positive, HER2-negative Advanced Breast Cancer (TIBET)

Breast Neoplasm | Chemotherapy Effect

Netherlands
Ora Bio Ltd.

Unknown

Pilot Study to Evaluate the Safety and Efficacy of Treatment With ORA102 Combined With Avastin (Bevacizumab) Versus Avastin Alone, in Patients With Neovascular Age Related Macular Degeneration (AMD)

Macular Degeneration

Israel
Amgen

Terminated

A Phase 3 Study of Rilotumumab (AMG 102) With Cisplatin and Capecitabine (CX) as First-line Therapy in Gastric Cancer (RILOMET-2)

Gastric Cancer

Korea, Republic of, Japan
Ipsen

Terminated

Evaluate the Safety, Tolerability, Biodistribution and Anti Tumour Activity of 177LU-OPS201 With Companion Imaging 68Ga-OPS202 PET/CT in Previously Treated Subjects With Locally Advanced or Metastatic Cancers Expressing Somatostatin Receptor 2 (SSTR2) (SSTR2+)

Small Cell Lung Cancer and Breast Cancer

United States, Austria, France, Switzerland, Germany, United Kingdom, Belgium
Bristol-Myers Squibb

Completed

Phase 1, Multiple Ascending Dose Study of Anti-HER2 FCAB FS102 in HER2 Positive Solid Tumors (Anti HER2 Fcab)

Solid Tumors That Overexpress HER2 (HER2 Positive)

United States, Canada
Omeros Corporation

Completed

A Randomized Study in Children Ages Birth Through Three Years Undergoing Unilateral Cataract Extraction With or Without Lens Replacement (ILR7)

Congenital Cataract | Unilateral Cataract Extraction

United States
University of Wisconsin, Madison
Ipsen

Recruiting

Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

United States
Taiho Oncology, Inc.
Institut de Recherches Internationales Servier

Completed

Phase III Study of Trifluridine/Tipiracil With and Without Bevacizumab in Refractory Metastatic Colorectal Cancer Patients (SUNLIGHT)

Refractory Metastatic Colorectal Cancer

United States, Poland, France, Germany, Hungary, Italy, Russian Federation, Ukraine, Austria, Belgium, Brazil, Denmark, Puerto Rico, Spain
Amgen

Terminated

First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma (RILOMET-1)

Gastric Cancer

United States, Italy, Belgium, Hungary, Poland, Romania, Denmark, Switzerland, Canada, France, Germany, Russian Federation, Turkey, United Kingdom, Spain, Austria, Portugal, Australia, Greece, South Africa, Bulgaria, Ukraine, Brazil, ... and more
UNICANCER

Completed

MEGA (Met or EGFR Inhibition in Gastroesophageal Adenocarcinoma): FOLFOX Alone or in Combination With AMG 102 or Panitumumab as First-line Treatment in Patients With Advanced Gastroesophageal Adenocarcinoma (MEGA)

Malignant Neoplasm of Stomach | Malignant Neoplasm of Esophagus

France
DEKA Biosciences

Recruiting

Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors

Kidney Cancer | Cancer | Head and Neck Cancer | Gynecologic Cancer | Colorectal Cancer | Solid Tumor | Non Small Cell Lung Cancer | Skin Cancer | Pancreas Cancer

United States

3

Subscribe